Adjudication of serious heart failure in patients from PROactive

Lancet

Volumn 369, Issue 9557, 2007, Pages 189-190

  Rydén, Lars ^a   Thráinsdóttir, Inga ^a   Swedberg, Karl ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE;

ACCURACY; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; ECHOCARDIOGRAPHY; HEART FAILURE; HUMAN; LETTER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOM; THORAX RADIOGRAPHY; WEIGHT GAIN;

EID: 33846222754     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60106-8     Document Type: Letter

References (5)

1. Dormandy J., Charbonnel B., Eckland E., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized trial of pioglitazone. Lancet 366 (2005) 1279-1289
2. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 366 (2005) 1241-1242
3. Guillausseau P.-J. PROactive study. Lancet 367 (2006) 23
4. Holman R., Retnakaran, Farmer A., and Stevens R. PROactive study. Lancet 367 (2006) 25
5. Swedberg K., Cleland J., Dargie H., et al., for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140